Author(s): Albrecht, P ; Bjørnå, K ; Brassat, D ; Farrell, R ; Feys, P ; Hobart, J ; Hupperts, R ; Linnebank, M ; Magdič, J ; Oreja-Guevara, C ; Pozzilli, C ; Salgado, AV ; Ziemssen, T
Date: 2018
Persistent ID: http://hdl.handle.net/10400.10/2056
Origin: Repositório do Hospital Prof. Doutor Fernando Fonseca
Subject(s): Multiple sclerosis; Quality of life; Fampridine
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts' opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.
